FDA 483 - Abid H. Khan MD - July 02, 2021

An FDA inspection of Abid H. Khan MD, a clinical investigator in Ontario, CA, revealed significant deficiencies in the conduct of clinical trials. Observations included inadequate investigational drug disposition records, lacking details on dispensed quantities, lot numbers, and subject compliance. Additionally, the Principal Investigator failed to review multiple adverse event reports, including one serious adverse event, indicating a lack of proper investigation into study-related issues.